Convergence Pharma, Selcia enter into drug discovery collaboration

As per the terms of the agreement, Convergence Pharma will apply its ion channel biology platform, medicinal chemistry know-how and preclinical development expertise, recently formed out of GlaxoSmithKline (GSK), to Selcia’s medicinal chemistry and chemistry support services.

Convergence Pharma Chemistry and Preclinical Development head Ged Giblin said that following the successful launch of Convergence Pharma with a $35m fund raising, and in-line with their business strategy, this collaboration uniquely enables their goal of identifying novel, high quality, targeted molecules for the treatment of chronic pain.

"We believe the combination of Convergence’s platform and Selcia’s bespoke approach will provide an innovative model for this drug discovery partnership in finding solutions for a major unmet clinical need," Giblin said.